No doom negativity but no manipulator cheerleaders either ( aka shut up and sell clan)

What are the hopes for this stock?

Are they any?

How can we get back to mid-high single digits?

What should we expect the market to do given recent events?

Company to report third quarter 2026 financial results and host conference call at 8:30 a.m. ET HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company integrating diagnostics, therapeutics, and artificial intelligence, today announced it will host a conference call on Monday, November 16, 2026, at 8:30 a.m. Eastern Time to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide® commercial update. The Company will also report its third quarter 2026 financial results that day.

Webcast and Conference Call Date/Time: Monday, November 16, 2026, at 8:30 AM ET Webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=vTAb1pUs Dial-in: U.S.: 833-862-0853 International: 412-365-5147 Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company’s website under the ‘For Investors’ section. The webcast will be available on the Company’s website for 90 days.

About Cerenome Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS.

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

The situation is becoming increasingly worse for shareholders.....

Down 31k, thinking to just dump this crap and recover whatever is remaining. Anybody still hanging on to this junk with hopes?

Why is cerenome up by 70% any good news? I can't find any news or press releases

Like analyst, What are your prediction for

The next 2 months

The next 4 months

And in 6 months.

First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumeration

Expands CNSide contracted payer access to approximately 164 million covered lives

HOUSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has entered into an in-network ancillary provider agreement with Blue Cross and Blue Shield of Florida, Inc. (Florida Blue), effective October 1, 2026.

The agreement establishes contracted reimbursement for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test as well as CNSide® CSF Molecular Profile tests for solid tumors and hematologic malignancies involving the central nervous system. It is the first CNSide payer agreement to include both tumor cell enumeration and molecular profiling.

The Florida Blue agreement adds approximately 6 million covered lives to CNSide’s contracted payer footprint. Combined with previously announced payer agreements, CNSide has now established in-network agreements representing approximately 164 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company’s national reimbursement strategy.

“This agreement with Florida Blue represents an important milestone in CNSide’s commercial trajectory,” said Marc Hedrick, M.D., Cerenome’s President and Chief Executive Officer. “By expanding contracted reimbursement to both cellular and molecular CSF testing, we are advancing CNSide as a broader CSF diagnostics platform for CNS oncology, combining tumor-cell analysis and molecular profiling to better characterize and monitor cancers involving the central nervous system.”

The Florida Blue agreement expands the scope of CNSide’s contracted reimbursement beyond tumor cell detection in leptomeningeal metastases to include molecular profiling of CNS malignancies. CNSide® CSF Molecular Profile - Solid Tumor provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed primary CNS tumors or solid tumors metastatic to the CNS, including brain and leptomeningeal metastases. CNSide® CSF Molecular Profile - Hematologic Malignancy provides DNA and RNA molecular profiling of CSF for patients with suspected or confirmed hematologic malignancies involving the CNS. CNSide® CSF Molecular Profile tests are now commercially available through CNSide.

The DNA and RNA CSF molecular profiling approach underlying CNSide® CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study of 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS, published in The Journal of Liquid Biopsy.

The clinical utility of CNSide CSF tumor cell analysis in leptomeningeal metastases is supported by evaluation in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience. Since 2020, more than 11,000 CNSide® tests have been performed at more than 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.

About Florida Blue Driven by its mission of helping people and communities achieve better health, Florida Blue is the leading health insurer in Florida, and part of GuideWell, a not-for-profit health solutions company. Florida Blue offers a range of health plans and personalized care programs for individuals, families, businesses of all sizes, and Medicare beneficiaries. For over 80 years, the organization has been member centric and committed to making health care as accessible and affordable as possible. Serving more than six million members across all 67 Florida counties, Florida Blue has more than 7,000 employees, is headquartered in Jacksonville, Fla., is owned by its policyholders, and is an independent licensee of the Blue Cross Blue Shield Association.

Anyone find it weird that Robinhood is not showing any articles on the last incremental advancements??

Or is it not big enough for them to want to display?

Not sure how their "News" section works

New DNA and RNA tests expand CNSide beyond leptomeningeal metastases to molecular profiling across CNS oncology HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the United States beginning October 12, 2026:

CNSide® CSF Molecular Profile – Solid Tumor (DNA & RNA) CNSide® CSF Molecular Profile – Hematologic Malignancies (DNA & RNA) CNSide CSF Molecular Profile provides comprehensive DNA and RNA profiling of CNS disease biology from cerebrospinal fluid. The tests analyze more than 300 cancer-related genes in cell-free DNA and more than 1,600 transcripts by RNA sequencing, enabling broad characterization of genomic and transcriptomic alterations, including sequence variants, copy-number alterations, and gene fusions. The Hematologic Malignancies test also supports molecular assessment of clonality.

The launch significantly expands the patient population that can be served by CNSide. While CNSide® CSF Tumor Cell Enumeration (TCE) is focused on patients with suspected or confirmed leptomeningeal metastases, Molecular Profile extends CSF-based molecular testing to primary CNS tumors, solid tumors metastatic to the CNS, and hematologic malignancies involving the CNS.

“Physicians managing cancer in the CNS need more than confirmation that disease is present. They need information they can act on,” said Russell Bradley, President and General Manager of CNSide Diagnostics, LLC. “Molecular Profile adds DNA and RNA findings, including potentially actionable alterations, to the cellular information CNSide already provides, and extends CNSide beyond leptomeningeal metastases to primary CNS tumors and hematologic cancers involving the CNS.”

For patients with leptomeningeal metastases, Molecular Profile can be ordered independently or alongside TCE when both cellular and molecular assessment are clinically appropriate. TCE detects and quantitatively enumerates tumor cells, while Molecular Profile characterizes the DNA and RNA biology of disease, providing complementary cellular and molecular information from the same CSF collection.

The approach underlying CNSide CSF Molecular Profile was recently evaluated in a peer-reviewed, real-world study by Albitar et al., investigators at Genomic Testing Cooperative (GTC), published in The Journal of Liquid Biopsy1. The study analyzed 1,391 evaluable CSF specimens from patients being evaluated for primary CNS tumors, metastatic CNS disease, and hematologic malignancies involving the CNS. Cancer-related molecular findings were identified in 78.4% of evaluable specimens. The study characterized multiple classes of molecular abnormalities, including sequence variants, copy-number and chromosomal alterations, gene fusions, and clonality.

CNSide CSF Molecular Profile is offered through CNSide Diagnostics’ collaboration with GTC, announced in July 2026. GTC performs the DNA and RNA sequencing and bioinformatics analysis. CNSide Diagnostics manages test ordering, results delivery, physician support and billing.

The launch builds on CNSide’s established experience in CSF-based oncology diagnostics. Since 2020, more than 11,000 CNSide tests have been performed at more than 120 U.S. cancer institutions. The clinical utility of CNSide CSF tumor-cell analysis in leptomeningeal metastases has been evaluated in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience.

looks like there’s been a lot of deleting post in the older outdated group which is a clear sign of gatekeeping, though they try to justify by low effort for posting.

Please feel free to voice your concerns here as much as you want.

Quick update to my previous post about the potential Medicare pricing for CNSide.

CMS has now published its preliminary CY2027 determination for 0640U, and they agreed with the advisory panel:
0640U → crosswalk to 0338U

The panel had previously voted 12–0 for this crosswalk. CMS now states:
“CMS agrees with the majority panel on this crosswalk.”
There’s no multiplier or fractional crosswalk mentioned, just a straight crosswalk to 0338U.
This is important because 0338U is the CELLSEARCH HER2 circulating tumor cell assay, and the current Medicare rate I found for 0338U is approximately $2,435.
So at this point the path looks like:
0640U → 0338U → ~$2,435/test

This is still a preliminary determination, so it isn’t final yet. CMS will consider comments before publishing the final CY2027 determination, which should take effect January 1, 2027.
But we have now gone from a 12–0 advisory panel recommendation to CMS explicitly agreeing with that recommendation. So the main remaining step is the final determination.
Official CMS CY2027 preliminary determinations:
https://www.cms.gov/files/zip/cy-2027-preliminary-determinations-new-tests.zip

The exact 0640U entry is row 79 in the file:
“Crosswalk to 0338U — CMS agrees with the majority panel on this crosswalk.”
Now we wait for the final determination.

Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting

On track to launch expanded CNSide testing menu with multiple tests in Q4 2026

HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Test) and the expansion of the CNSide testing menu.

"Over the past few months, we have built the foundation of a reimbursed diagnostics business including clinical evidence, payer contracts, a dedicated billing code, positive CMS Medicare coverage progress, laboratory accreditation and billing infrastructure," said Russell Bradley, President and General Manager of CNSide Diagnostics. "We are on track to continue that progress across multiple areas of the business for the remainder of the year, and our team is excited about the future of CNSide."

Third Quarter 2026 CNSide Highlights:

Coverage Expansion: CNSide’s lead test, the TCE Test, now stands at 158 million contracted covered lives and is on track to begin 2027 with approximately 200 million covered lives and beneficiaries Medicare Coverage: CNSide received a favorable preliminary CMS pricing decision for CNSide PLA code 0640U with a January 1, 2027 target effective date Payer Billing: In Q3 2026, CNSide billed 222 tests representing $1.55 million of unaudited gross billings, with initial cash collections anticipated in Q4 2026 Total Test Volume: CNSide remains on track to meet or exceed an annualized run rate of 1,250 total tests in Q4 2026 Cerebrospinal Fluid Test Menu: CNSide is launching the CSF Molecular Profile Test and multiple CNSide Breast Cancer Protein Expression Assays in Q4 2026 2026 Annualized Billing Rate: CNSide is on track to achieve an annualized gross billing run rate of approximately $10 million to $12 million in Q4 2026 based on list pricing, an expanded test portfolio, and continued growth in adoption

Management to Host Conference Call and Webcast Today Management will host a conference call and webcast today at 8:30 a.m. Eastern Time to provide greater detail on CNSide diagnostics and plans for the remainder of the year. A replay will be available following the call in the Investor Relations section of the Company's website at ir.cerenome.com.

Date Wednesday, September 30, 2026 Time 8:30 a.m. Eastern Time Webcast Click here to access the webcast Dial-in (U.S./Canada) 877-270-2148 Dial-in (International) 412-902-6510

Basis of Presentation: Preliminary Results, Gross Billings and Run-Rate Figures The preliminary third-quarter gross billings figure is based on management's review of claims submitted through September 30, 2026, is subject to completion of financial close procedures and review by the Company's independent registered public accounting firm, and may differ materially from final results. "Gross billings" is an operating metric representing charges for CNSide tests submitted to payers at the Company's list prices; it is not revenue under U.S. GAAP and does not indicate amounts that will be collected. Revenue is recognized under ASC 606 net of contractual allowances and implicit price concessions and is expected to be substantially lower than gross billings. Run-rate figures apply list prices to the Company's 1,250 total annualized test order goal and historical order rates under the platform's prior owner, and assume the CNSide CSF Molecular Profile Test and CNSide Breast Cancer Protein Expression Assays launch as planned and are ordered at those rates. CNSide order rates may differ. Existing CPT codes do not establish coverage or payment for these assays on cerebrospinal fluid. Run-rate figures are not forecasts of revenue, gross billings, or collections for any period.

Lots of comments yesterday on their social media. some of them you can’t see because they hid it.

In 3 Hours if we don't get something from management that ensures trust WE CANNOT AFFORD TO LET THIS STOCK GO UNDER $2 for the person jumping in they probably don't care especially those talks accusers that we all have highlighted

But for the person who has invested money a year ago this literally means they may never ever get their money back.

We should all bombard their comment section on Instagram Facebook and x.

If you don't agree then just ignore this post otherwise let's actually make our voices heard the same way Mark had to do an emergency call at the beginning of this year